HTA reports

The reports completed (in Estonian, with summary in English) are published as a series of publications and are available both electronically at https://tervis.ut.ee/et/tervisetehnoloogiate-hindamine-0 and in print.

HTA reports in production (as of May 2020):

TTH51 Robotic magnetic navigation for treatment of cardiac arrhythmia

TTH50 Genetic testing for cancer treatment strategies

TTH49 New methods for screening for prostate cancer

TTH48 Screening for lung cancer

TTH47 Biologic drugs in dermatology

TTH46 Buprenorphine as a substitute treatment for opiate dependence 

TTH45 Effectiveness and cost-effectiveness of HPV vaccines

 

Completed HTA reports

TTH44 Home health visits in the early postpartum period

TTH43 The budget impact analysis of smoking cessation interventions in Estonia

TTH42 The efficacy and cost-effectiveness of quadrivalent influenza vaccine

TTH41 Polysomnography

TTH40 Newborn screening for galactosemia

TTH39 Cost-effectiveness of hepatitis C treatment in Estonia

TTH38 Cost-effectiveness of antiretroviral drugs in the first-line treatment of HIV-infected patients in Estonia

TTH37 The cost-effectiveness of using antiretroviral drugs in HIV-negative people

TTH36 Home enteral nutrition service in Estonia

TTH35 The cost-effectiveness of diabetic retinopathy screening in Estonia

TTH34 The cost-effectiveness of IDegLira, IGlarLixi and liraglutide or lixisenatide added to basal insulin in patients with uncontrolled type 2 diabetes mellitus in Estonia

TTH33 The clinical effectiveness and cost-effectiveness of GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus in Estonia

TTH32 Screening programme for abdominal aortic aneurysm in Estonia

TTH31 Cost-effectiveness of the Estonian cervical cancer screening programme: Pap versus HPV testing

TTH30 The effectiveness of safe injection facilities

TTH29 Combining antiretroviral treatments with methadone maintenance in HIV-positive drug users in Estonia

TTH28 Cost-effectiveness of treatment strategies in patients with metastatic lung cancer

TTH27 The cost-effectiveness of treatment strategies for patients with mutiple myeloma

TTH26 The effectiveness and cost-effectiveness of prostate cancer screening in Estonia

TTH25 The costs and cost-effecitiveness of BCG vaccination in Estonia

TTH24 The cost-effectiveness of continuous subcutaneous insulin infusion for patients with type I diabetes

TTH23 Ranolazine for treatment of stable angina

TTH22 Mammography screening for breast cancer

TTH21 The cost-effectiveness of chemotherapy for HER-2 positive metastatic breast cancer

TTH20 The cost-effectiveness of HPV vaccination

TTH19 The cost-effectiveness of  pneumococcal vaccine in Estonia

TTH18 Healthcare costs and resource utilization in treatment of preterm births in Estonia

TTH17 The cost-effectiveness of biologic vs synthetic disease modifying antirheumatic drugs in rheumatoid arthritis

TTH16 The cost-effectiveness of depot antipsychotic therapy

TTH15 The cost-effectiveness of EGFR inhibitors in colorectal cancer treatment

TTH14 Naloxone programme to prevent overdose deaths in Estonia

TTH13 The cost-effectiveness of tick-borne encephalitis vaccination in Estonia

TTH12 The cost-effectiveness of seasonal influenza vaccination

TTH11 The cost-effectiveness of colorectal cancer screening

TTH10 Cost-effectiveness of new oral anticoagulants in Estonia

TTH09 Anti-hyperglycaemic medicines sitagliptin and dapagliflozin

TTH08 Indications and costs of polysomnography and pulse oximetry in Estonia

TTH07 Effectiveness and costs of treatment strategies in patients with multiple myeloma

TTH06 Cost-effectiveness of Vemurafenib in the treatment of metastatic melanoma

TTH05 Mammography screening for breast cancer

TTH04 Effectiveness and costs of in vitro fertilisation (IVF) in Estonia

TTH03 Continuous subcutaneous insulin infusion in children with type 1 diabetes

TTH02 Ventricular assist device efficiency and cost-effectiveness in heart failure

TTH01 Effectiveness and cost-effectiveness of biologic vs synthetic disease-modifying drugs in rheumatoid arthritis